In 2024, GLP-1 prescriptions were dominated by primary care physicians, endocrinologists, and telehealth platforms. In 2026, a new category has entered the market with force: medical spas.
Med spas — hybrid facilities offering aesthetic procedures under physician supervision — have been adding GLP-1 prescribing to their service menus at an accelerating rate. The appeal is obvious: the same clientele that pays for body contouring, lipolysis, and skin rejuvenation is the ideal demographic for weight loss medication. The cross-sell practically writes itself.
But prescribing injectable GLP-1 agonists is not the same as administering Botox. The clinical requirements, monitoring standards, and adverse event management are fundamentally different. And the med spa model — optimized for episodic aesthetic procedures, not ongoing chronic disease management — often lacks the infrastructure for safe GLP-1 prescribing.
What's happening
Three forces are driving med spa GLP-1 adoption:
Revenue pressure. The aesthetic market softened in late 2025 as consumer spending shifted. GLP-1 prescribing offers a new, high-margin revenue stream with a subscription model (recurring monthly payments) that aesthetic procedures (episodic, one-time) don't provide. A patient on GLP-1 autoship is worth $2,400-4,800 per year in recurring revenue. A Botox patient is worth $600-1,200 per year.
Patient demand. Patients are asking their aesthetic providers about GLP-1 medications. "My injector recommended it" is a common referral pathway, and aesthetic patients already have a transactional relationship with injection-based treatments that reduces the barrier to starting.
Regulatory permissiveness. In most states, prescribing GLP-1 medications doesn't require specific credentials beyond an active medical license (or NP/PA license with prescriptive authority). There's no "GLP-1 certification" or "weight management board certification" required to prescribe. If you can legally write a prescription, you can legally prescribe semaglutide.
Where med spas fall short
Intake and screening
GLP-1 medications have specific contraindications: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, and several others. A proper intake requires a thorough medical history, medication reconciliation, and — ideally — baseline labs. Many med spas use the same lightweight intake form for GLP-1 that they use for aesthetic procedures, missing contraindications that a more robust screening would catch.
Titration and monitoring
Proper GLP-1 prescribing follows a titration schedule — starting at the lowest dose and gradually increasing based on tolerance and response. This requires structured follow-up at each dose adjustment. Med spas typically operate on an appointment basis, not a longitudinal care model. A patient who gets their initial GLP-1 prescription at a med spa may not have a structured follow-up protocol in place — and may increase their dose based on a brief phone consultation or a text message rather than a clinical assessment.
Side-effect management
GLP-1 side effects — nausea, vomiting, constipation, pancreatitis risk, gallbladder complications — require clinical assessment and sometimes intervention. Med spa staff are trained in aesthetic procedure management, not GI symptom triage. A patient calling their med spa with severe nausea and dehydration after a dose increase may get a response calibrated for "Botox didn't wear off" rather than "potential GI emergency."
Pharmacy sourcing
Some med spas source compounded GLP-1 medications from pharmacies that also supply their aesthetic products — relationships built on Botox and filler supply chains, not pharmaceutical-grade compounding oversight. The quality bar for a pharmacy supplying hyaluronic acid filler is different from the quality bar for a pharmacy compounding injectable peptide medications. Cross-category sourcing without additional diligence introduces risk.
When med spa GLP-1 prescribing works
Not every med spa GLP-1 program is a problem. The ones that work share these features:
A dedicated weight management program. Not GLP-1 bolted onto the menu next to chemical peels. A structured program with intake protocols, titration schedules, follow-up cadences, and defined clinical pathways for common side effects. The program looks like a medical program because it is one.
A clinician with relevant training. The prescribing clinician has training or experience in obesity medicine, endocrinology, or internal medicine — not exclusively in aesthetics. Ideally, they hold an ABOM (American Board of Obesity Medicine) certification or equivalent.
Separate pharmacy relationships. The GLP-1 medication comes from a compounding pharmacy selected for its pharmaceutical capabilities, not from the same supplier that provides filler and neurotoxin. The pharmacy is named and verifiable.
After-hours clinical coverage. Side effects don't respect business hours. A med spa that prescribes GLP-1 medications needs to provide after-hours clinical contact — even if it's through a telehealth service — for patients experiencing adverse events.
The bottom line
GLP-1 prescribing requires more than a prescription pad. It requires intake screening for contraindications, a titration protocol, structured follow-up, side-effect management infrastructure, and pharmacy quality assurance. Some med spas have built this. Many haven't.
If your med spa offers GLP-1 medications, apply the same scrutiny you'd apply to any telehealth platform. The setting doesn't determine the quality — the clinical infrastructure behind it does. And if the infrastructure isn't there, a dedicated GLP-1 telehealth provider with proven clinical protocols is the safer choice.